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Abstract
Background: To evaluate the feasibility and therapeutic effect of chemotherapy combined with
regional radio frequency hyperthermia for pretreated locally advanced non-small cell lung cancer.
Methods: 29 patients with stage III non-small cell lung cancer were enrolled in present study,
received chemotherapy up to 4 cycles and radio frequency hyperthermia up to 32 times. The
primary end points were grade 3,4 hematological or non-hematological toxicities and progression
free survival, the secondary end points were response rate, tumor control rate and overall survival.
Method of Kaplan-Meier was used for the survival analysis.
Results: 21 patients completed their arranged treatments. The most common grade 3,4 toxicity
was neutropenia (24.1%). Median progression free survival was 4 months (range 0–13 months), one
year progression free survival rate was 10.3%. Overall response rate was 25.9%, tumor control rate
was 66.6%. Median overall survival was 11 months (range 2–18+ months), one year overall survival
rate was 44.8%.
Conclusion: Treatment of chemotherapy in conjunction with regional hyperthermia was safe and
well tolerant, it suggested an impressive tumor control rate and an acceptable one year progression
free survival. Further study might be needed.
Background
Non-small cell lung cancer accounts for at least 80% of all
lung neoplasma, and about 35% of these patients present
with locally advanced unresectable disease [1]. Systemic
chemotherapy with the platinum-containing regimens
plus concurrent regional radiation is generally accepted as
the standard first-line treatment for inoperable locally
advanced non-small cell lung cancer, meta-analysis con-
firmed the response and survival benefits, but the large
number of patients will experience disease progression or
tumor relapse [2-6]. For patients with a good performance
status, second-line chemotherapy is recommended. Sev-
eral third-generation chemotherapeutic agents had been
evaluated in the second line setting, docetaxel maybe the
most extensively studied one [7-10]. Recent studies indi-
cated that second-line chemotherapy with docetaxel
weekly as a single-agent regimen for pretreated non-small
cell lung cancer was well tolerant and had an acceptable
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response rate and a reasonable median survival time
about 26.1 weeks [7,11,12]. Obviously, neither physi-
cians nor patients are satisfied with this.
Empirical studies indicated that heat played a lethal effect
to human tumor cell lines, and heat enhanced cytotoxic
effect of chemotherapeutics [13-15]. Along with the devel-
opment of technology, hyperthermia improves therapeu-
tic effect of superficial tumors, soft tissue sarcoma,
osteosarcoma, prostate cancer, breast cancer and some
recurrent or advanced solid tumors [16-21]. There are rare
reports that demonstrate the advantage of adding hyper-
thermia to chemotherapy as the second-line therapy for
pretreated locally advanced non-small cell lung cancer. In
present study, we combined docetaxel weekly chemother-
apy with external regional radio frequency (RF) hyperther-
mia as the second-line treatment for patients with
inoperable stage III non-small cell lung cancer who had
failed to response to the prior platinum-containing chem-
otherapy. The toxicities and progression free survive (PFS)
were primarily investigated.
Methods
Patients selection
Eligible patients must had histological or cytological
proof to be inoperable stage IIIa or IIIb non-small cell
lung cancer, and should have at least one measurable
lesion. They experienced only one platinum-containing
regimen as the first-line treatment, whether accompanied
with irradiation or not. They failed to respond to the first-
line treatment, and proved to be still inoperable by spiral
computed tomograph. In addition, patients should be
with a ECOG performance status ≤ 2, and have normal
hematological index (neutrophil count ≥ 2 × 109/l, plate-
let count ≥ 100 × 109/l, haemoglobin ≥ 100 g/l) and
acceptable biochemical analysis result (normal bilirubin
level, alanine aminotransferase ≤ 2.5 × upper limit of nor-
mal (ULN) and serum creatinine level ≤ 1.5 × ULN).
Patients with metal foreign matter, fever (≥ 38°C), signif-
icant hemorrhagic tendency, and seriously impaired func-
tion of lung or heart were excluded. Every patient enrolled
in this study had signed a written informed consent form
approved by Si Chuan University Hua Xi Medical Ethics
Committee, which also approved the study protocol.
Chemotherapy regimen
A regimen of docetaxel 40 mg/m2 intravenous infusion on
day1, 8 and 15, repeated every 4 weeks was chosen.
Docetaxel was administered intravenously within 1 hour.
Prophylactic oral corticosteroid premedication (dexame-
thasone 8 mg) was given 3 times over 2 days. Target sum
of chemotherapy would be 4 cycles.
Dose adjustment should be done when grade 4 hemato-
logical or grade 3,4 non-hematological toxicities
appeared, a dose reduction was of 25% in subsequent
cycles. Docetaxel infusion could not be delayed for over 2
weeks since patient discontinuation.
Hyperthermia regimen
We used a radio frequency external heat system (Ho Kai
company, China) working frequency was 13.8 MHz to
perform regional hyperthermia. Primary lesion was cho-
sen to be the target area, covered by an applicator 20 cm
in diameter. Hyperthermia was administered 1 hour after
chemotherapeutics were given, the total heated time was
up to 60 minutes, twice a week, aimed to 32 times, inter-
val between 2 procedures should exceed 48 hours. Target
temperature ranged from 41°C to 43°C, we instructed
every patient to mention any abnormal feelings, so that
we could adjust settings such as power output, or place a
water bolus to ease the uncomfortable.
Evaluation of response and toxicity
The response had been estimated within a week after every
2 cycles of chemotherapy were given, and to be confirmed
in 4 weeks of responding patients. We used contrast-
enhanced spiral computed tomograph to measure the
largest diameter of target tumor, response criteria was
based on Response Evaluation Criteria In Solid Tumors
(RECIST)[22]. Toxicity evaluation was done in all patients
according to NCI CTC version 2.0 [23].
Follow up
Eligible patients were visited once a month after treatment
starting, their PFS and overall survival (OS) time was
recorded. Disease evaluation was performed every 3
months or when necessary. The time limit of follow-up
was 18 months in present study.
Statistical analysis
Main objective of present study was to evaluate the safety
and therapeutic effect of docetaxel weekly chemotherapy
combined with RF hyperthermia for pretreated locally
advanced non-small cell lung cancer. The primary end
points were grade 3,4 hematological or non-hematologi-
cal toxicities and PFS, the secondary end points were
response rate, tumor control rate and OS.
Kaplan-Meier survival curve was used to describe PFS and
OS. Statistical work was performed by soft ware SPSS 13.0
(SPSS Inc. USA). Lost patients were recorded as death,
their PFS were calculated up to the last visit as well as OS,
except they had already experienced tumor progression.
Results
Patients' characteristics
From June 2005 to December 2005, 29 pretreated patients
with stage III non-small cell lung cancer were included in
this study, 8 patients in stage IIIb accompanied with pleu-BMC Cancer 2007, 7:189 http://www.biomedcentral.com/1471-2407/7/189
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ral effusion, who were not suitable for radiation. And
other 10 patients refused to sign the informed consent
form for radiotherapy. Overview of this study was fully
explained to every eligible patient, every enrolled patient
had signed an informed consent form and asked to keep
one copy. Patients' characteristics were presented in Table
1.
Treatment exposure
249 docetaxel infusions and 626 times of hyperthermia
were administered totally. Median dosage of docetaxel
was 40 mg/m2 (range, 30–40 mg/m2), median endurable
temperature was 42.3°C (range, 41.3–43.0°C). There
were 13 patients (44.8%) completing 4 cycles of chemo-
therapy and 32 times of hyperthermia, 2 patients (6.9%)
had been administered only 1 cycle of chemotherapy and
2 times of hyperthermia.
Toxicity
8 patients (27.6%) discontinued study treatment, 6 of
them due to toxicities: 4 because of grade 3 neutropenia,
and 2 because of grade 4 neutropenia; the other 2 patients
withdrew their informed consent form. No patient termi-
nated treatment because of the side effect of RF hyperther-
mia.
6 patients (20.7%) experienced a dose reduction to 30
mg/m2 due to toxicities (5 patients due to neutropenia, 1
patient due to arthralgia).
Treatment delays were applied in 5 patients (17.2%), 4
delays occurred due to neutropenia, the other one
occurred due to abnormal level of alanine aminotrans-
ferase (>2.5 × ULN).
3 patients (10.3%) experienced grade 1 empyrosis after
heated, no related treatment was administered. This side
effect released in 48 hours, not even one time of hyper-
thermia was delayed for this reason.
Main toxicities were summarized in Table 2.
Response
There were 27 patients (93.1%) who had been evaluated
for response. No patient achieved a complete remission
(CR), 7 patients (25.9%) achieved a partial remission
(PR), 11 patients (40.7%) were evaluated as a stable dis-
ease (SD), and 9 patients (33.3%) experienced a progres-
sion disease (PD). Overall response rate was 25.9%,
tumor control rate (CR + PR + SD) was 66.6%.
Survival analysis
The median follow-up time was 16 months (range 12–18
months), 4 patients (13.8%) were lost at follow up, their
PFS/OS (months) was recorded as following: 0/2, 0/2, 0/
5, 0/7. Median PFS was 4 months (range 0–13 months,
95% CI: 1.9–6.1 months), one year progression free sur-
vival rate was 10.3% (Figure 1). Median OS was 11
months (range 2–18+  months, 95% CI: 9.3–12.8
months), one year survival rate was 44.8% (Figure 2). At
the time of analysis, 5 patients were still alive.
Table 2: Main toxicities per patient
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Hematological
Hemoglobin 2(6.9%) 0 0 0
Neutrophils 5(17.2%) 4(13.8%) 5(17.2%) 2(6.9%)
Platelets 1(3.4%) 1(3.4%) 0 0
Non-hematological
Palpitation 1(3.4%) - - -
Edema 2(6.9%) 1(3.4%) 0 0
Fatigue 6(20.7%) 2(6.9%) 0 0
Sweating 4(13.8%) 0 - -
Weight loss 3(10.3%) 1(3.4%) 0 -
Alopecia 5(17.2%) 2(6.9%) - -
Nausea 5(17.2%) 2(6.9%) 1(3.4%) -
Taste disturbance 1(3.4%) 0 - -
Vomiting 2(6.9%) 3(10.3%) 0 0
SGOT (AST) 3(10.3%) 0 1(3.4%) 0
SGPT (ALT) 1(3.4%) 1(3.4%) 1(3.4%) 0
Insomnia 3(10.3%) 0 0 -
Arthralgia 2(6.9%) 0 1(3.4%) 0
Headache 2(6.9%) 0 0 0
M y a l g i a 001 ( 3 . 4 % ) 0
Table 1: Patients' characteristics
Characteristics Number of patients Percentage
Patients treated 29 -
Age
Median 57 -
Range 35–72 -
Gender
Male 21 72.4
Female 8 27.6
Histological subtype
Squamous carcinoma 11 37.9
Adenocarcinoma 18 62.1
Stage
IIIa (T2N2M0/T3N2M0) 12 (8/4) 41.4
IIIb (T2N3M0/T4N1M0/T4N2M0) 17 (2/8/7) 58.6
ECOG performance status
01 2 4 1 . 4
11 2 4 1 . 4
25 1 7 . 2
Prior chemotherapy (cycles)
Gemcitabine and cisplatin 14 (46) 48.3%
Vinorelbine and cisplatin 8 (21) 27.6%
Paclitaxel and cisplatin 7 (26) 24.1%
Prior radiotherapy 11 37.9%BMC Cancer 2007, 7:189 http://www.biomedcentral.com/1471-2407/7/189
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Discussion
Docetaxel is recommended for second-line chemotherapy
of non-small cell lung cancer, and weekly administration
regimen showed a good safety, but recent studies resulted
that the response rate and survive was still poor [12].
There are rare studies about hyperthermia for lung cancer,
even it had been reported to improve the therapeutic effi-
cacy in some drug insensitive tumors such as prostate can-
cer and soft tissue sarcoma [17,18,20].
Structure of vascular in malignant tissue is great different
from normal tissue, it was reported that the blood flow
rate in normal tissue would be 30 times greater than
tumor tissue [24]. This difference makes temperature of
tumor tissue significantly higher than normal tissue under
the same heat condition. Cytotoxic effect of several antitu-
mor agents include docetaxel can be enhanced by raising
temperature [25]. Hyperthermia also shows as a comple-
mentation of radiotherapy [26]. RF hyperthermia is pow-
ered by electromagnetic wave of a certain wavelength, it
has the ability to go through whole human body and
transforms to heat when different mediator encountered.
Current study was designed to evaluate feasibility and effi-
cacy of docetaxel plus RF hyperthermia for patients failed
to response to prior platinum-containing chemotherapy.
A total of 29 eligible patients enrolled in present study, 12
patients were of stage IIIa, 17 patients were of stage IIIb.
21 patients (72.4%) completed the arranged study treat-
ment, while 8 patients (27.6%) discontinued. Main
hematological toxicity was neutropenia, 7 patients
(24.1%) experienced Grade 3,4 neutropenia, most of
them were grade 3. With G-CSF hypodermic injection,
this toxicity was well controlled. None of grade 4 non-
hematological toxicities was observed, but grade 3 nausea,
transaminase increasing, arthralgia and myalgia had been
observed. Only 3 patients experienced grade 1 empyrosis,
and they all self-recovered. Results above showed the
comparable toxicities[7,11], it might indicate that
regional RF hyperthermia does not increase the toxicity of
chemotherapy.
The therapeutic efficacy of the study treatment was accept-
able, a response rate of 25.9% and a tumor control rate of
66.6% were better than docetaxel alone. A median PFS of
4 months and a median OS of 11 months might not be
satisfied, but compared with docetaxel alone (median OS
ranged from 6.4 to 9.2 months), these results were
encouraging [7,8].
Conclusion
Docetaxel weekly regimen in conjunction with regional
RF hyperthermia acted as the second-line treatment for
pretreated locally advanced non-small cell lung cancer
was safe and well tolerant. The results of current study also
suggested advantages in response and survival. A further
phase III study is supported by these results.
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